LISATA THERAPEUTICS, INC. (LSTA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
LISATA THERAPEUTICS, INC. (LSTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 9, 2026, Lisata Therapeutics, Inc. (the “ Company ”) held its 2026 annual meeting of stockholders (the “ Annual
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The new plans increase the authorized share pool, introducing dilution risk, while the reverse split proposal could alter share price dynamics.
Market read
The filing provides fresh corporate‑action data that may affect share supply and investor sentiment, but the immediate market impact is expected to be modest.
What to watch
Potential impact on employee retention and future fundraising capacity is not reflected in the immediate price move.
Background
Lisata Therapeutics filed an 8‑K detailing shareholder approvals of equity incentive plans, an ESPP, board elections, and a reverse split range.
Ticker impact
SEC Form 8‑K reports approval of a new 2026 Equity Incentive Plan and ESPP, plus board elections and a reverse split proposal, providing fresh corporate‑action details.
likely slight downward pressure as market prices in future dilution from the 2026 plans
The filing discloses new share reserves (44.8M for the plan, 3.7M for ESPP) and a potential reverse split, both material to equity valuation.
Market effects
Minimal; primarily affects biotech‑sector micro‑cap investors tracking dilution risk.
U.S. market only; no broader regional effect.
Low; the filing is company‑specific without macro implications.
Counterpoint
The dilution may be offset by future financing needs, and the reverse split could boost price perception.
Key entities
- companyLisata Therapeutics, Inc.
Biotech firm filing the 8‑K.
- personCynthia L. Flowers
Elected Class I director.
- personDr. Ted W. Love, M.D.
Elected Class I director.
